111 related articles for article (PubMed ID: 31299252)
1. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
Chen C; Li F; Ma MM; Zhang S; Liu Y; Yan ZL; Chen W; Cao J; Zeng LY; Wang XY; Xu KL; Wu QY
Int J Biol Macromol; 2019 Sep; 137():1030-1040. PubMed ID: 31299252
[TBL] [Abstract][Full Text] [Related]
2. Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells.
Wu QY; Ma MM; Tong YX; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2018 Oct; 117():271-279. PubMed ID: 29842959
[TBL] [Abstract][Full Text] [Related]
3. Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
Wu QY; Ma MM; Zhang S; Cao J; Yan ZL; Chen C; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Sep; 136():209-219. PubMed ID: 31199972
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia.
Li F; Lu ZY; Xue YT; Liu Y; Cao J; Sun ZT; Zhang Q; Xu MD; Wang XY; Xu KL; Wu QY
Int J Biol Macromol; 2023 Feb; 229():247-259. PubMed ID: 36529225
[TBL] [Abstract][Full Text] [Related]
5. Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Wu QY; Ma MM; Zhang S; Liu Y; Cao J; Yan ZL; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Mar; 124():1123-1131. PubMed ID: 30521925
[TBL] [Abstract][Full Text] [Related]
6. Effects of the I682F mutation on JAK2's activity, structure and stability.
Li F; Li W; Liu Y; Tong YX; Zhou P; Wang L; Chen C; Zeng LY; Wu QY; Wang XY; Xu KL
Int J Biol Macromol; 2015 Aug; 79():118-25. PubMed ID: 25940527
[TBL] [Abstract][Full Text] [Related]
7. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
[TBL] [Abstract][Full Text] [Related]
8. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
[TBL] [Abstract][Full Text] [Related]
9. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
10. Essential thrombocytosis attributed to JAK2-T875N germline mutation.
Yoshimitsu M; Hachiman M; Uchida Y; Arima N; Arai A; Kamada Y; Shide K; Ito M; Shimoda K; Ishitsuka K
Int J Hematol; 2019 Nov; 110(5):584-590. PubMed ID: 31428969
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
12. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
13. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
14. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
[TBL] [Abstract][Full Text] [Related]
16. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
17. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN
PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M
Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039
[TBL] [Abstract][Full Text] [Related]
19. Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation.
Wu QY; Li F; Guo HY; Cao J; Chen C; Chen W; Zhao K; Zeng LY; Han ZX; Li ZY; Wang XY; Xu KL
Arch Biochem Biophys; 2012 Dec; 528(1):57-66. PubMed ID: 22960131
[TBL] [Abstract][Full Text] [Related]
20. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
